Fig. 2From: Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro Dox and AD198 induced ROS in human TCC cells. (a) T24 and (b) UMUC3 cells were treated with 1μM Dox and AD198 for 24 h and ROS levels were measured with dihydrogen-dichlorodihydro-fluoresceindiacetate assay; percent of ROS positive cells were measured and normalized to the control. Values represent mean ± S.E. of three independent experiments. Paired Student t- tests were used to compare Doxand AD198 treatments to controls, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Paired Student t-tests were used to compare among Dox and AD198 group at the same dose treatment; #p ≤ 0.05 and ##p ≤ 0.01Back to article page